PT  - JOURNAL ARTICLE
AU  - Zambrana, Jose Victor
AU  - Hasund, Chloe M.
AU  - Aogo, Rosemary A.
AU  - Bos, Sandra
AU  - Arguello, Sonia
AU  - Gonzalez, Karla
AU  - Collado, Damaris
AU  - Miranda, Tatiana
AU  - Kuan, Guillermina
AU  - Gordon, Aubree
AU  - Balmaseda, Angel
AU  - Katzelnick, Leah
AU  - Harris, Eva
TI  - Primary exposure to Zika virus increases risk of symptomatic dengue virus infection with serotypes 2, 3, and 4 but not serotype 1
AID  - 10.1101/2023.11.29.23299187
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.11.29.23299187
4099  - http://medrxiv.org/content/early/2023/11/30/2023.11.29.23299187.short
4100  - http://medrxiv.org/content/early/2023/11/30/2023.11.29.23299187.full
AB  - Infection with any of the four dengue virus serotypes (DENV1-4) can protect against or enhance subsequent dengue depending on pre-existing antibodies and the subsequent infecting serotype. Additionally, primary infection with the related flavivirus Zika virus (ZIKV) has been shown to increase DENV2 disease. Here, we measured how prior DENV and ZIKV immunity influenced risk of disease caused by all four serotypes in a pediatric Nicaraguan cohort. Of 3,412 participants in 2022, 10.6% experienced symptomatic DENV infections caused by DENV1 (n=139), DENV4 (n=133), DENV3 (n=54), DENV2 (n=9), or an undetermined serotype (n=39). Longitudinal clinical and serological data were used to define infection histories, and generalized linear and additive models adjusted for age, sex, time since the last infection, cohort year, and repeat measurements were used to predict disease risk. Compared to flavivirus-naïve participants, primary ZIKV infection increased disease risk of DENV4 (relative risk = 2.62, 95% confidence interval: 1.48-4.63) and DENV3 (2.90, 1.34-6.27) but not DENV1 (1.20, 0.72-1.99). Primary DENV infection or a DENV followed by ZIKV infection also increased DENV4 risk. We re-analyzed 19 years of cohort data and demonstrated that prior flavivirus-immunity and pre- existing antibody titer differentially affected disease risk for incoming serotypes, increasing risk of DENV2 and DENV4, protecting against DENV1, and protecting at high titers but enhancing at low titers against DENV3. We thus find that prior ZIKV infection, like prior DENV infection, increases risk of certain DENV serotypes. Cross-reactivity among flaviviruses should be carefully considered when assessing vaccine safety and efficacy.One-Sentence Summary Dengue disease risk is differentially modulated depending on pre- existing immunity to dengue and Zika virus infections and the secondary infecting serotype.Competing Interest StatementEH's laboratory received research funds from Takeda Vaccines Inc. to test samples from vaccine recipients. EH served on one-time advisory boards for Merck and Takeda. AG served on an RSV vaccine scientific advisory board for Janssen.Funding StatementThis work was supported by National Institutes of Health grants P01AI106695 (EH), U19AI118610 (EH) and R01AI099631 (AB), Pediatric Dengue Vaccine Initiative grant VE-1 (EH), the Bill and Melinda Gates Foundation - FIRST grant (EH), and the Division of Intramural Research of the National Institute of Allergy and Infectious Diseases (LCK).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The human subjects protocol of the Pediatric Dengue Cohort Study was reviewed and approved by the Institutional Review Boards of the University of California, Berkeley (2010-09-2245), the University of Michigan (HUM00091606), and the Nicaraguan Ministry of Health (CIRE-09/03/07-008). Parents or legal guardians of all subjects provided written informed consent. Participants aged 6 years of age and older provided assent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data pertinent to this study can be found within the paper or the Supplementary Materials. and the associated code is available for reference on Zenodo. After securing approval from the UC Berkeley Committee for the Protection of Human Subjects, individual data for figure reproduction could be shared with external researchers. For data access arrangements, please contact EH at eharris{at}berkeley.edu. Standard data and material transfer agreements govern all materials and data used in this study.